Effects of Stimulation of Soluble Guanylate Cyclase on Diabetic Nephropathy in Diabetic eNOS Knockout Mice on Top of Angiotensin II Receptor Blockade

The prevalence of diabetes mellitus and its complications, such as diabetic nephropathy (DN), is rising worldwide and prevention and treatment are therefore becoming increasingly important. Therapy of DN is particularly important for patients who do not adequately respond to angiotensin receptor blocker (ARB) treatment. Novel approaches include the stimulation of soluble guanylate cyclase (sGC) as it is reported to have beneficial effects on cardiac and renal damage. We aimed to investigate the effects of the sGC stimulator riociguat and ARB telmisartan on kidney function and structure in a hypertensive model of diabetic nephropathy. Seventy-six diabetic male eNOS knockout C57BL/6J mice were randomly divided after having received streptozotocin: telmisartan (1 mg/kg/d), riociguat (3 mg/kg/d), riociguat+telmisartan (3+1 mg/kg/d), and vehicle. Fourteen mice were used as non-diabetic controls. Treatment duration was 11 weeks. Glucose concentrations were increased and similar in all diabetic groups. Telmisartan insignificantly reduced blood pressure by 5.9 mmHg compared with diabetic controls (111.2±2.3 mmHg vs. 117.1±2.2 mmHg; p = 0.071). Treatment with riociguat both alone and in combination with telmisartan led to a significant reduction of blood pressure towards diabetic vehicle (105.2±2.5 mmHg and 105.0±3.2 mmHg, respectively, vs. 117.1±2.2 mmHg). Combined treatment also significantly decreased albuminuria compared with diabetic controls (47.3±9.6 µg/24 h vs. 170.8±34.2 µg/24 h; p = 0.002) reaching levels similar to those of non-diabetic controls (34.4±10.6 µg/24 h), whereas the reduction by single treatment with either telmisartan (97.8±26.4 µg/24 h) or riociguat (97.1±15.7 µg/24 h) was not statistically significant. The combination treatment led to a significant (p<0.01) decrease of tissue immunoreactivity of malondialdehyde, as consequence of reduced oxidative stress. In conclusion, stimulation of sGC significantly reduced urinary albumin excretion in diabetic eNOS knockout mice treated already with ARB. Thus, this new drug class on top of standard ARBs administration may offer a new therapeutic approach for patients resistant to ARB treatment.

[1]  O. V. Evgenov,et al.  Soluble Guanylate Cyclase Stimulation Prevents Fibrotic Tissue Remodeling and Improves Survival in Salt-Sensitive Dahl Rats , 2011, PloS one.

[2]  Pál Pacher,et al.  Soluble guanylate cyclase as an emerging therapeutic target in cardiopulmonary disease. , 2011, Circulation.

[3]  M. Cooper,et al.  Diabetic nephropathy in 2010: Alleviating the burden of diabetic nephropathy , 2011, Nature Reviews Nephrology.

[4]  R. Schmieder,et al.  Renal protection in diabetes: lessons from ONTARGET® , 2010, Cardiovascular diabetology.

[5]  J. Stasch,et al.  Nitric oxide-independent stimulation of soluble guanylate cyclase reduces organ damage in experimental low-renin and high-renin models , 2010, Journal of hypertension.

[6]  Diederick E. Grobbee,et al.  The global burden of diabetes and its complications: an emerging pandemic , 2010, European journal of cardiovascular prevention and rehabilitation : official journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology.

[7]  S. Matsuo,et al.  eNOS knockout mice with advanced diabetic nephropathy have less benefit from renin-angiotensin blockade than from aldosterone receptor antagonists. , 2010, The American journal of pathology.

[8]  C. Alpers,et al.  Mouse models of diabetic nephropathy. , 2005, Journal of the American Society of Nephrology : JASN.

[9]  J. Stasch,et al.  Cardioprotective effects in aged spontaneously hypertensive rats due to chronic stimulation/activation of sGC without hypotension , 2009, BMC Pharmacology.

[10]  J. Stasch,et al.  Pressure-independent effects of pharmacological stimulation of soluble guanylate cyclase on fibrosis in pressure-overloaded rat heart , 2009, Hypertension Research.

[11]  J. Stasch,et al.  Discovery of Riociguat (BAY 63‐2521): A Potent, Oral Stimulator of Soluble Guanylate Cyclase for the Treatment of Pulmonary Hypertension , 2009, ChemMedChem.

[12]  W. Seeger,et al.  Expression and function of soluble guanylate cyclase in pulmonary arterial hypertension , 2008, European Respiratory Journal.

[13]  W. Almawi,et al.  Association of endothelial nitric oxide synthase Glu298Asp, 4b/a, and -786T>C gene variants with diabetic nephropathy. , 2008, Journal of diabetes and its complications.

[14]  F. Brosius.  New insights into the mechanisms of fibrosis and sclerosis in diabetic nephropathy , 2008, Reviews in Endocrine and Metabolic Disorders.

[15]  S. Yusuf,et al.  Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial , 2008, The Lancet.

[16]  S. Yusuf,et al.  Telmisartan, ramipril, or both in patients at high risk for vascular events. , 2008, The New England journal of medicine.

[17]  C. Tomson,et al.  Comorbidities in UK patients at the start of renal replacement therapy (chapter 6). , 2007, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[18]  K. Amann,et al.  Blood Pressure-Independent Effect of Long-Term Treatment with the Soluble Heme-Independent Guanylyl Cyclase Activator HMR1766 on Progression in a Model of Noninflammatory Chronic Renal Damage , 2007, Kidney and Blood Pressure Research.

[19]  M. Gannon,et al.  Deficiency of endothelial nitric-oxide synthase confers susceptibility to diabetic nephropathy in nephropathy-resistant inbred mice. , 2007, The American journal of pathology.

[20]  B. Croker,et al.  Diabetic endothelial nitric oxide synthase knockout mice develop advanced diabetic nephropathy. , 2007, Journal of the American Society of Nephrology : JASN.

[21]  J. Stasch,et al.  Soluble Guanylate Cyclase Stimulation on Cardiovascular Remodeling in Angiotensin II–Induced Hypertensive Rats , 2006, Hypertension.

[22]  R. Wolterbeek,et al.  Clinical and histologic determinants of renal outcome in ANCA-associated vasculitis: A prospective analysis of 100 patients with severe renal involvement. , 2006, Journal of the American Society of Nephrology : JASN.

[23]  E. Antunes,et al.  Protective Effects of BAY 41-2272 (sGC Stimulator) on Hypertension, Heart, and Cardiomyocyte Hypertrophy Induced by Chronic L-NAME Treatment in Rats , 2006, Journal of cardiovascular pharmacology.

[24]  D. Levy,et al.  Low-Grade Albuminuria and Incidence of Cardiovascular Disease Events in Nonhypertensive and Nondiabetic Individuals: The Framingham Heart Study , 2005, Circulation.

[25]  Luiz Pinho,et al.  Endothelial dysfunction is correlated with microalbuminuria in children with short-duration type 1 diabetes. , 2005, Diabetes care.

[26]  Nicoletta Pellegrini,et al.  A review of recent studies on malondialdehyde as toxic molecule and biological marker of oxidative stress. , 2005, Nutrition, metabolism, and cardiovascular diseases : NMCD.

[27]  H. Kawachi,et al.  Stimulation of soluble guanylate cyclase slows progression in anti-thy1-induced chronic glomerulosclerosis. , 2005, Kidney international.

[28]  D. Haffner,et al.  Systemic cardiovascular disease in uremic rats induced by 1,25(OH)2D3 , 2005, Journal of hypertension.

[29]  J. Stasch,et al.  Stimulation of soluble guanylyl cyclase inhibits mesangial cell proliferation and matrix accumulation in experimental glomerulonephritis. , 2005, American journal of physiology. Renal physiology.

[30]  C. Reid,et al.  Why blockade of the renin-angiotensin system reduces the incidence of new-onset diabetes. , 2005, Journal of hypertension.

[31]  N. Futrakul,et al.  Letter To The Editor: Early Detection of Endothelial Dysfunction and Early Therapeutic Correction Effectively Restore Renal Function in Type 2 Diabetic Nephropathy , 2005 .

[32]  H. Neumayer,et al.  Expression and activity of soluble guanylate cyclase in injury and repair of anti-thy1 glomerulonephritis. , 2004, Kidney International.

[33]  T. Berl,et al.  Pathogenesis of Diabetic Nephropathy , 2004, Reviews in Endocrine and Metabolic Disorders.

[34]  E. Antunes,et al.  PROTECTIVE EFFECT OF BAY 41-2272 (SGC STIMULATOR) ON HYPERTENSION AND HEART HYPERTROPHY INDUCED BY CHRONIC L-NAME TREATMENT IN RATS: OP 071 , 2004 .

[35]  S. Martini,et al.  NO mediates antifibrotic actions of L-arginine supplementation following induction of anti-thy1 glomerulonephritis. , 2003, Kidney international.

[36]  K. Iseki,et al.  Proteinuria and the risk of developing end-stage renal disease. , 2003, Kidney international.

[37]  Hans L Hillege,et al.  Urinary Albumin Excretion Predicts Cardiovascular and Noncardiovascular Mortality in General Population , 2002, Circulation.

[38]  P. Doevendans,et al.  The Glu298Asp polymorphism of the NOS 3 gene as a determinant of the baseline production of nitric oxide , 2002, Journal of hypertension.

[39]  J. Stasch,et al.  Cardiovascular actions of a novel NO‐independent guanylyl cyclase stimulator, BAY 41‐8543: in vivo studies , 2002, British journal of pharmacology.

[40]  J. Shaw,et al.  Global and societal implications of the diabetes epidemic , 2001, Nature.

[41]  R. Gerzer,et al.  NO-independent regulatory site on soluble guanylate cyclase , 2001, Nature.

[42]  S. Hong,et al.  THE KEY ROLE OF THE TRANSFORMING GROWTH FACTOR-β SYSTEM IN THE PATHOGENESIS OF DIABETIC NEPHROPATHY , 2001 .

[43]  B. Hocher,et al.  ETA receptor blockade induces fibrosis of the clipped kidney in two‐kidney‐one‐clip renovascular hypertensive rats , 2000, Journal of hypertension.

[44]  D. Moczulski,et al.  Risk of advanced diabetic nephropathy in type 1 diabetes is associated with endothelial nitric oxide synthase gene polymorphism. , 2000, Kidney international.

[45]  A. Papagianni,et al.  Factors influencing the course and the response to treatment in primary focal segmental glomerulosclerosis. , 2000, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[46]  G. Kajiyama,et al.  A comparison of angiotensin-converting enzyme inhibitors, calcium antagonists, beta-blockers and diuretic agents on reactive hyperemia in patients with essential hypertension: a multicenter study. , 2000, Journal of the American College of Cardiology.

[47]  KazuwaNakao,et al.  T−786→C Mutation in the 5′-Flanking Region of the Endothelial Nitric Oxide Synthase Gene Is Associated With Coronary Spasm , 1999 .

[48]  K. Nakao,et al.  T-786-->C mutation in the 5'-flanking region of the endothelial nitric oxide synthase gene is associated with coronary spasm. , 1999, Circulation.

[49]  N. Clausell,et al.  Increased expression of tumor necrosis factor-alpha in diabetic macrovasculopathy. , 1999, Cardiovascular pathology : the official journal of the Society for Cardiovascular Pathology.

[50]  T. Miyata,et al.  Immunohistochemical evidence for an increased oxidative stress and carbonyl modification of proteins in diabetic glomerular lesions. , 1999, Journal of the American Society of Nephrology : JASN.

[51]  Y. Kawaguchi,et al.  Evidence of association of the ecNOS gene polymorphism with plasma NO metabolite levels in humans. , 1998, Biochemical and biophysical research communications.

[52]  V. Monnier,et al.  Immunohistochemical colocalization of glycoxidation products and lipid peroxidation products in diabetic renal glomerular lesions. Implication for glycoxidative stress in the pathogenesis of diabetic nephropathy. , 1997, The Journal of clinical investigation.

[53]  E. S. St. Clair,et al.  Clinical, biochemical and pathological predictors of poor response to intravenous cyclophosphamide in patients with proliferative lupus nephritis. , 1996, Clinical nephrology.

[54]  B. Brenner,et al.  Prevention of diabetic glomerulopathy by pharmacological amelioration of glomerular capillary hypertension. , 1986, The Journal of clinical investigation.

[55]  M. Steffes,et al.  Structural-functional relationships in diabetic nephropathy. , 1984, The Journal of clinical investigation.

[56]  S. Satchell,et al.  Diabetic nephropathy. , 2012, Clinical medicine.

[57]  N. Futrakul,et al.  Early detection of endothelial injury and dysfunction in conjunction with correction of hemodynamic maladjustment can effectively restore renal function in type 2 diabetic nephropathy. , 2006, Clinical hemorheology and microcirculation.

[58]  H. Kawachi,et al.  Enhancing cGMP in experimental progressive renal fibrosis: soluble guanylate cyclase stimulation vs. phosphodiesterase inhibition. , 2006, American journal of physiology. Renal physiology.

[59]  Maristela L Onozato,et al.  Oxidative stress and nitric oxide synthase in rat diabetic nephropathy: effects of ACEI and ARB. , 2002, Kidney international.